Temgicoluril
Clinical data | |
---|---|
Trade names | Adaptol, Mebicar |
Other names | Adaptol; Mebicar; Mebicarum; Mebikar; Tetramethylglycoluril; 1,3,4,6-Tetramethylglycoluril |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Gastrointestinal tract: 77–80% |
Elimination half-life | 3 hours[1] |
Excretion | Urine: 55–70% |
Identifiers | |
| |
JSmol) | |
| |
|
Temgicoluril (
The chemical structure of temgicoluril is somewhat similar to uric acid and it doesn't interact with acids, alkali, oxidants and reducing agents. It seems to affect all major neurotransmitter systems.[4]
Temgicoluril has an effect on the structure of limbic–reticular activity, particularly on hypothalamus emotional zone, as well as on all several basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin, and adrenergic activity. It decreases brain norepinephrine levels and increases brain serotonin levels without modulating dopaminergic systems or cholinergic systems.[5]
Temgicoluril purportedly has anti-anxiety (anxiolytic) properties.
It can be prepared by condensation of N,N-dimethylurea with glyoxal. One publication described such a procedure. They combined N,N-dimethylurea and glyoxal with a catalytic amount of phosphoric acid anhydride in an aqueous solution at room temperature and after sufficient time temgicoluril was conveniently isolated by filtration. The filtrate can be re-used by adding more dimethylurea and glyoxal (no additional catalyst is needed) and obtaining respectable yields, although this requires a longer reaction time.[11]
As of 2021, temgicoluril has not been evaluated outside of Latvia and Russia.
Medical uses
Temgicoluril is used in Latvia and Russia, as a
Temgicoluril does not have a direct effect on sleep, however, it enhances the effectiveness of sleep medicines and normalizes the course of disturbed sleep. Temgicoluril alleviates or eliminates the manifestations of nicotine dependence that occur after smoking cessation. Although temgicoluril does not cause mood swings or euphoria, habituation, nor addiction, withdrawal syndrome has been observed.[contradictory]
Side effects
Possible and rare side effects may include dizziness, hypotension, indigestion, allergic reactions (itchy skin) after high doses, hypothermia, fatigue. And lowered blood pressure and/or body temperature decreased by 1 to 1.5 °C. Blood pressure and body temperature return to normal after completion of treatment.[12]
See also
- Fabomotizole
- Phenibut
- Selank
- Validol
- Bemethyl
References
- ^ US 20110070305, Schwarz J, Weisspapir M, "Sustained release pharmaceutical composition containing mebicar", published 2011-03-24, assigned to Alpharx Inc.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (3). 2020.
- ^ a b c "Adaptol product summary". JSC Olainfarm. Latvia. Archived from the original on 2013-10-13. Retrieved 2013-05-29.
- ^ "Clinical Overview ADAPTOL" (PDF). JSC Olainfarm. Latvia. Archived (PDF) from the original on 8 September 2021.
- ^ PMID 6104993.
- ^ S2CID 11343572.
- PMID 23534281.
- PMID 22678674.
- PMID 21183919.
- PMID 19738569.
- S2CID 96318579.
- ^ "Adaptol (Mebicarum) - Summary of product characteristics". State Agency of Medicines of Latvia (in Latvian). Archived from the original on 7 August 2021.